Non in Medical Technology
Navigation Links
Non in Medical Technology
... Squamous, Which Differentiates Squamous From non Squamous non Small Cell Lung Cancer, With Current Diagnostic ... which differentiates squamous from non
squamous non small cell lung cancer, with available ...
... Approximately 185,000 people are diagnosed with non Small Cell Lung Cancer each year in the United ... technology, differentiating squamous from non squamous non small cell lung cancer, is now approved ...
... test based on the company's technology, differentiating squamous from non squamous non small cell lung cancer, is now approved through Columbia University ...
... Canada, Mexico, the Dominican Republic and the Bahamas, to make the non invasive therapy available. USHIFU is also funding FDA-approved clinical ... different sites. About the Sonablate(R) 500 The Sonablate(R) 500 is a non invasive medical device that utilizes ultrasound energy to destroy tissue ...
... at: www.pnas.org/cgi/doi/10.1073/pnas.0405220101 . Accessed on 5 May 2009. Riely G. J. et al. "Clinical Course of Patients with non -Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib." Clin. Cancer Res, ...
... heat within the prostate. This results in the focal destruction of prostatic tissue. High Intensity Focused Ultrasound does not use radiation and is non surgical. In a small U.S. safety trial, 91 percent of the participants treated in the study had a negative biopsy at six months. Some men ...
... North America. Novexel retains worldwide rights on the NXL104/ceftazidime combination. About NXL104 NXL104 is a novel injectable non beta lactam, beta-lactamase inhibitor, which is being developed to address the increasing problem of microbial resistance to beta lactam antibiotics ...
... California. www.westly.org Global Health Research Foundation Global Health Research Foundation is a Los Altos, CA-based 501C non profit providing community-based, sustainable health methodologies and tools for use by local health workers worldwide. www.ghrf.org ...
... of severe or fatal hemoptysis (internal bleeding in the lungs) to overall poor response. Current methods for differentiating squamous from non squamous non-small cell lung cancer lack standardization, are difficult to reproduce, and have low accuracy. Studies that reviewed the accuracy and ...
... media materials, visit www.gskcancermedia.com GSK Enquiries: Onsite Media enquiries: Greg Clarke - non US media only +1 610 405 0053 Ken Inchausti - US media only +1 267 809 7552 UK Media enquiries: Philip ...
... was in patients given warfarin (7.8 percent, 10.6 percent and 3.2 percent, respectively). In contrast, the incidence of major and clinically relevant non major bleeding events with the 30 and 60 mg once-daily DU-176b regimens was comparable to that with warfarin (3.0 percent, 3.8 percent, and 3.2 ...
... in North America. Novexel retains worldwide rights on the NXL104/ceftazidime combination. About NXL104 NXL104 is a novel injectable non beta lactam, beta-lactamase inhibitor, which is being developed to address the increasing problem of microbial resistance to beta lactam antibiotics ...
... structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability to deliver siRNA non invasively to target tissues including the eye, ear, kidney, lung, spinal cord and brain. PF-4523655 (RTP801i-14), currently in Phase II clinical ...
... demonstrated a half-life of approximately 26 days for IV administration. Valortim(R) has been tested in both the New Zealand White (NZW) rabbit and non human primate models to evaluate its efficacy in the post-exposure prophylaxis and therapeutic settings. In the post-exposure setting, Valortim(R) ...
... public announcements by major HIV opinion leaders and pharmaceutical companies of their disappointing results despite significant investments in non productive vaccine strategies, attention is now beginning to refocus on the mucosa approach. Mymetics, with a robust IP portfolio and having ...
... to symptom exacerbation than patients who received the reference dose and that the four-week 405 mg and the pooled two-week dosing regimens showed non inferiority when compared to oral olanzapine and to each other. About Olanzapine LAI Post-Injection Syndrome Analysis As with all medications, ...
... options are needed." About the Study To participate in the study, patients had to be at least 60 years of age or at least 18 years of age and non suitable for intensive chemotherapy combination treatment, with a WHO performance status 0 or 1. The EORTC's protocol called for a maximum of 6 ...
... in the U.S. HIFU clinical trials. For more information about the clinical trials eligibility criteria call USHIFU at 1-877-874-4389. "HIFU offers non invasive treatment option for men who are looking for a therapy that will not completely disrupt their lives. A story on a prominent news program, ...
... lung cancer diagnostic tests, specifically, through identifying unique microRNA signatures that may predict risk of recurrence in stage I and II non Small Cell Lung Cancer (NSCLC) patients, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private ...
... Stage IV disease is six months. Treatment of melanoma depends on the stage of the disease with surgical resection being effective in less severe non metastatic forms of the disease. However, survival rates for later Stage III and IV patients are poor, reflecting the lack of any efficacious drugs ...
... the identification and diagnosis of brain malignancies. 6. "MicroRNAs as a diagnostic tool for differentiating squamous cell lung cancer from other non small cell lung cancers" Lung cancer is the leading cause of cancer-related death among men and women. Of all lung cancer cases, 80% are ...
... that are used to create its human and animal therapeutic agents. The most advanced human product candidate for Bioniche is Urocidin(TM) to treat non muscle-invasive bladder cancer. Urocidin(TM) entered Phase III clinical development in late 2006 after receiving Fast Track status from the U.S. Food ...
... Approximately 185,000 people are diagnosed with non Small Cell Lung Cancer each year in the United ... technology, differentiating squamous from non squamous non small cell lung cancer, is now approved ...
Pharmasset Reports Fiscal Year End 2008 Financial Results
... 19% (3 of 16) in the control group. Further results in genotype 2 and 3, non responder patients treated with 1500mg BID generated RVR rate of 90% (18 ... RENT 79,793 204,256 non CURRENT PORTION OF CAPITAL LEASE OBLIGATION ...... test based on the company's technology, differentiating squamous from non squamous non small cell lung cancer, is now approved through Columbia University ...
Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum
... test based on the company's technology, differentiating squamous from non squamous non small cell lung cancer, is now approved through Columbia University ...... Canada, Mexico, the Dominican Republic and the Bahamas, to make the non invasive therapy available. USHIFU is also funding FDA-approved clinical ... different sites. About the Sonablate(R) 500 The Sonablate(R) 500 is a non invasive medical device that utilizes ultrasound energy to destroy tissue ...
XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
... MACE at 30 days, the rate was 2.2 percent, consisting of two in-hospital non Q-wave myocardial infarctions (MIs). At six-month follow-up the MACE rate ... CUSTOM III was 7.8 percent. There were zero deaths, zero Q-wave MIs, two non Q-wave MIs, or 2.2 percent, and five clinically driven target lesion ...Progen Announces PI-88 Phase 2 Lung Cancer Results
... with the chemotherapeutic agent docetaxel to patients with advanced non small cell lung cancer did not meet its primary endpoint of significantly ... investigation of PI-88 in combination with docetaxel in patients with non small cell lung cancer that have failed platinum based first line ...Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
... glucose levels, increase the body's sensitivity to insulin, and reduce fat mass and body weight in animals. Isis partnered with non profit foundations to pursue new treatments for debilitating diseases, such as severe neurodegenerative diseases. Isis was awarded a grant ...Alfacell Provides Shareholder Update
... thought, consideration, and input from highly respected lung experts, we have decided our path moving forward would be to conduct a clinical trial in non small cell lung cancer (NSCLC) in patients who have become resistant to platinum therapy. Dr. David Sidransky (Alfacell Chairman of the Board) is ...... at: www.pnas.org/cgi/doi/10.1073/pnas.0405220101 . Accessed on 5 May 2009. Riely G. J. et al. "Clinical Course of Patients with non -Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib." Clin. Cancer Res, ...
AACR Data Highlights InNexus Preclinical Antibody Candidate
... announced today that the company will be presenting new data on its lead preclinical candidate DXL625 (CD20) for the prospective treatment of non Hodgkin's Lymphoma (NHL) at the annual meeting of the American Association for Cancer Research (AACR), April 18-22, in Denver. "Preclinical data ...Major Restless Legs Study Completes Enrollment With Support From MediciGlobal
... ensure that site staff could handle the workflow and no RLS patients were lost in the screening process. "The team approached this project in a non traditional way," says Moench. "The sponsor was open and willing to fresh ideas and marketing techniques, and clinical trial site enthusiastically ...... heat within the prostate. This results in the focal destruction of prostatic tissue. High Intensity Focused Ultrasound does not use radiation and is non surgical. In a small U.S. safety trial, 91 percent of the participants treated in the study had a negative biopsy at six months. Some men ...
ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM) Platform
... About Institute Gustave Roussy The Institut Gustave Roussy (IGR, Villejuif, France), European leading Comprehensive Cancer Center, is a non profit academic entity belonging to the French public hospital service and that is authorized to receive donations and legacies. IGR is a center ...... North America. Novexel retains worldwide rights on the NXL104/ceftazidime combination. About NXL104 NXL104 is a novel injectable non beta lactam, beta-lactamase inhibitor, which is being developed to address the increasing problem of microbial resistance to beta lactam antibiotics ...
... California. www.westly.org Global Health Research Foundation Global Health Research Foundation is a Los Altos, CA-based 501C non profit providing community-based, sustainable health methodologies and tools for use by local health workers worldwide. www.ghrf.org ...
... of severe or fatal hemoptysis (internal bleeding in the lungs) to overall poor response. Current methods for differentiating squamous from non squamous non-small cell lung cancer lack standardization, are difficult to reproduce, and have low accuracy. Studies that reviewed the accuracy and ...
... media materials, visit www.gskcancermedia.com GSK Enquiries: Onsite Media enquiries: Greg Clarke - non US media only +1 610 405 0053 Ken Inchausti - US media only +1 267 809 7552 UK Media enquiries: Philip ...
... was in patients given warfarin (7.8 percent, 10.6 percent and 3.2 percent, respectively). In contrast, the incidence of major and clinically relevant non major bleeding events with the 30 and 60 mg once-daily DU-176b regimens was comparable to that with warfarin (3.0 percent, 3.8 percent, and 3.2 ...
... in North America. Novexel retains worldwide rights on the NXL104/ceftazidime combination. About NXL104 NXL104 is a novel injectable non beta lactam, beta-lactamase inhibitor, which is being developed to address the increasing problem of microbial resistance to beta lactam antibiotics ...
Tackling Atrial Fibrillation and Associated Cardiovascular Risk
... -- to better understand the impact of dronedarone on hospitalization of AF patients particularly on the number and duration of CV and non CV hospitalization nights -- An additional sub-analysis was also conducted to further explore dronedarone's rhythm and rate controlling ...... structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability to deliver siRNA non invasively to target tissues including the eye, ear, kidney, lung, spinal cord and brain. PF-4523655 (RTP801i-14), currently in Phase II clinical ...
... demonstrated a half-life of approximately 26 days for IV administration. Valortim(R) has been tested in both the New Zealand White (NZW) rabbit and non human primate models to evaluate its efficacy in the post-exposure prophylaxis and therapeutic settings. In the post-exposure setting, Valortim(R) ...
... public announcements by major HIV opinion leaders and pharmaceutical companies of their disappointing results despite significant investments in non productive vaccine strategies, attention is now beginning to refocus on the mucosa approach. Mymetics, with a robust IP portfolio and having ...
... to symptom exacerbation than patients who received the reference dose and that the four-week 405 mg and the pooled two-week dosing regimens showed non inferiority when compared to oral olanzapine and to each other. About Olanzapine LAI Post-Injection Syndrome Analysis As with all medications, ...
Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
... Total current liabilities 11,083,924 10,936,045 DEFERRED RENT 111,164 204,256 non CURRENT PORTION OF CAPITAL LEASE OBLIGATION - 41,641 DEFERRED REVENUE 4,333,257 5,726,131 ...... options are needed." About the Study To participate in the study, patients had to be at least 60 years of age or at least 18 years of age and non suitable for intensive chemotherapy combination treatment, with a WHO performance status 0 or 1. The EORTC's protocol called for a maximum of 6 ...
Amicus Therapeutics Announces Second Quarter 2008 Financial Results
... million. The Company also stated that it does not expect to raise cash from any equity financings in 2008. The differences between U.S. GAAP and non U.S. GAAP financial results are itemized in Tables 2 and 3, and are primarily due to: -- Pre-tax stock compensation expense -- Pre-tax charges ...Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
... 14,304 23,952 Stockholders equity 60,696 75,991 Total liabilities, non controlling interest and stockholders' equity $122,279 $149,125 (1) Derived from audited consolidated financial statements at ...Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
... hyaluronan (HA), consistent with the selective reduction of tumor interstitial fluid pressure (IFP). Treatment with PEGPH20 was well tolerated in non tumor-bearing mice without significant increases in neutropenia (depletion of neutrophils, a type of white blood cell) compared to chemotherapy ....GeoVax Reports Progress on Its AIDS Vaccine Technology
... SIV infection, conventional anti-viral drug therapy was given to the primates to reduce the viral RNA infection levels to very low levels creating a non progressor status for the primate. Then the SIV prototype vaccine for the GeoVax AIDS vaccine was administered. Six weeks following the final ...Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
... global sales expected to be around $350-400 million, based on current expectation of the competitive environment - Expected to be accretive for non GAAP earnings by the second half of 2010 - Acquisition to bring worldwide rights to FIRAZYR (Icatibant), a peptide based therapeutic for HAE ...... in the U.S. HIFU clinical trials. For more information about the clinical trials eligibility criteria call USHIFU at 1-877-874-4389. "HIFU offers non invasive treatment option for men who are looking for a therapy that will not completely disrupt their lives. A story on a prominent news program, ...
New Australian Technology: Detecting Breast Cancer With Hair
... standard' for detecting the disease is mammography. According to Fermiscan's CEO, David Young, "The Fermiscan Test has the potential to provide a non invasive, fast and accurate addition to existing technologies for the detection of breast cancer in women of all ages. This test is not aimed at ...As Summer Heats Up, New Survey Reveals Need for Effective Sweat Treatments
... and head, among other areas, and though not caused by heat, is aggravated by heat or anxiety. The International Hyperhidrosis Society (IHHS), a non profit organization dedicated to those who have the condition, commissioned Harris Interactive to conduct a survey among nearly 3,000 U.S. adults to ...... lung cancer diagnostic tests, specifically, through identifying unique microRNA signatures that may predict risk of recurrence in stage I and II non Small Cell Lung Cancer (NSCLC) patients, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private ...
... Stage IV disease is six months. Treatment of melanoma depends on the stage of the disease with surgical resection being effective in less severe non metastatic forms of the disease. However, survival rates for later Stage III and IV patients are poor, reflecting the lack of any efficacious drugs ...
... the identification and diagnosis of brain malignancies. 6. "MicroRNAs as a diagnostic tool for differentiating squamous cell lung cancer from other non small cell lung cancers" Lung cancer is the leading cause of cancer-related death among men and women. Of all lung cancer cases, 80% are ...
... that are used to create its human and animal therapeutic agents. The most advanced human product candidate for Bioniche is Urocidin(TM) to treat non muscle-invasive bladder cancer. Urocidin(TM) entered Phase III clinical development in late 2006 after receiving Fast Track status from the U.S. Food ...
Other ContentsmycosismycoplasmamycoplasmamycoplasmamyelomamyelomamyelomamyelomamyelomamyelomagravismyastheniamyelitisinfarctioninfarctioninfarctioninfarctioninfarctionOther TagsCYPCYPCYP
(Date:12/2/2009)... HOBOKEN, NJ According to the National Institute ...iagnosed with diabetes already have some stage of ...e to the retina caused by leaky blood vessels, is ... and is one of the most feared diabetic complicati...o,ve had diabetes for 10 years or more will experi...
(Date:12/1/2009)... OptiNose is pleased to announce the publication o...gating the efficacy and tolerability of its novel,...eatment of chronic rhinosinusitis with nasal polyp...rnational and European Rhinologic Societies. , ...nic disease that can significantly reduce a patien...
(Date:12/1/2009)...available in German . , Brown adipose tissue ...s of mitochondria, miniature power stations which... they normally generate a voltage similar to that ...lar processes. However, the mitochondria of brown ... ahead all the time. The energy released when the ...
Breaking Biology News(10 mins):Study shows pine bark improves circulation, swelling and visual acuity in early diabetic retinopathy 2Study shows pine bark improves circulation, swelling and visual acuity in early diabetic retinopathy 3New data on highly effective treatment for chronic rhinosinusitis with nasal polyps 2Brown fat cells make 'spare tires' shrink 2ResMed Acquires Laboratoires Narval 5240 1ResMed Acquires Laboratoires Narval 5240 2ResMed Acquires Laboratoires Narval 5240 3GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT 28TM 29 5235 1GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT 28TM 29 5235 2GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT 28TM 29 5235 3Mediterranean Diet May Help Prevent Depression 58895 1Mediterranean Diet May Help Prevent Depression 58895 2Mediterranean Diet May Help Prevent Depression 58895 3(Date:12/2/2009)...S, Dec. 2 Proving true the old ada... Health Harris Methodist Hospital Southlake (THHMH...es Toys for Tots program to make the holiday seaso...rganizations are combining their efforts to collec...rishable food items, culminating in a final event ...
(Date:12/2/2009)...ad microbes in tobacco, but risk is unclear , ... research provides evidence that the average cigar...at cause respiratory disease. , But as one spok...rs of the new study aren,t sure what, if any, haza...hing new: Microbes surround us every day of our li...
(Date:12/2/2009)...lic beverages popular among youths are more likely...dership than alcoholic drinks consumed mainly by a...exposure to such targeted alcohol ads, according t...rsity School of Public Health, Johns Hopkins Bloom...sources who conducted the study -- published in t...
(Date:12/2/2009)...may seem like unlikely heroes in the battle agains... insects already used to study dozens of human di...ting that fruit flies can be used as a simpler and...ects of cocaine and other drugs of abuse on the br...euroscience , a new monthly journal. , Andrew E...
(Date:12/2/2009)...How do fruit flies get high cholesterol and become...t that,s too rich in fats. , More importantly, a... Utah human geneticist, fruit flies use the same m...per balances of cholesterol and a key form of stor...ean that as researchers try to learn more about th...
Breaking Medicine News(10 mins):Health News:Texas Health Harris Methodist Hospital Southlake Joins With U.S. Marine Corps Reserves Toys for Tots to Spread Holiday Cheer 2Health News:Smokers Inhaling Germs With Each Cigarette 2Health News:Alcohol companies target youths with magazine ads, new study shows 2Health News:Latest epidemic? High cholesterol, obesity in fruit flies 2Health News:Latest epidemic? High cholesterol, obesity in fruit flies 3[0] Texas Health Harris Methodist Hospital Southlake Joins With U.S. Marine Corps Reserves Toys for Tots to Spread Holiday Cheer[0] Smokers Inhaling Germs With Each Cigarette[0] Alcohol companies target youths with magazine ads, new study shows[0] The buzz on fruit flies: New role in the search for addiction treatments[0] Latest epidemic? High cholesterol, obesity in fruit flies
HematologicalSophisticatedSubfractionsPreanalyticalCYPMethicillinProliferatingTestingHowBNTMCBCIITrephinationBioresorbableTelehealthRTX3370
Other Tagsarrhythmias 2detected 2detected 3detected 4detected 5detected 6detected 7detected 8detected 9detected 10oestrogen 2oestrogen 3urged 2urged 3urged 4urged 5urged 6urged 7urged 8urged 9urged 10remember 2remember 3cheaper 2cheaper 3
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |